Sign up Australia
Proactive Investors - Run By Investors For Investors

Aquinox Pharmaceuticals shares slump after restructuring plan disclosed

The company said it has approved a restructuring plan to reduce operating costs and better align the company's workforce with the needs of its business.
Aquinox Pharmaceuticals shares slump after restructuring plan disclosed
Shares have tumbled more than 85% in recent weeks on the back of disappointing clinical trial results

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares slumped 5.5% in afternoon trading today after it announced it has approved a restructuring plan to reduce operating costs.

Shares were at US$2.43 on Tuesday, tumbling more than 85% in recent weeks on the back of disappointing clinical trial results from the company's Phase 3 LEADERSHIP 301 clinical trial. The company announced last month that the group’s cystitis drug failed to meet its main goal.

The treatment, oral rosiptor (AQX-1125), did not show a statistically significant reduction in bladder pain, according to the company, which is headquartered in Vancouver,  Canada.

READ: Aquinox Pharmaceuticals to stop development of leading cystitis drug; shares slump

The company announced Tuesday that it has halted all further development activities with rosiptor. 

Under the new restructuring plan, the company has reduced its workforce by 30 employees and closed its office in San Bruno, California.

In connection with the restructuring, the company said that it will incur aggregate restructuring charges of approximately $2.5M related to one-time termination severance payments and other employee-related costs and the shut-down of its San Bruno office.

The firm said the majority of the cash payments related to the personnel-related restructuring charges will be paid during the third quarter of 2018, with the remainder to be paid during the fourth quarter of 2018.

Shares of Aquinox were at US$2.43 in afternoon trading on Tuesday. 

 

View full AQXP profile View Profile

Aquinox Pharmaceuticals, Inc. Timeline

Related Articles

Widecells
September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use